Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression
Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disord...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/74a55e187b2b41f495aeae82377f4f6f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:74a55e187b2b41f495aeae82377f4f6f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:74a55e187b2b41f495aeae82377f4f6f2021-12-03T05:02:24ZAssociation of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression1664-064010.3389/fpsyt.2021.780975https://doaj.org/article/74a55e187b2b41f495aeae82377f4f6f2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fpsyt.2021.780975/fullhttps://doaj.org/toc/1664-0640Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia item at baseline, day 13 and 26. Plasma VEGF concentrations were examined at the same time points as the MADRS.Results: Despite a significant reduction in anhedonia symptoms in individuals with treatment-refractory MDD (n = 59) or BD (n = 19) after they received repeated-dose ketamine infusions (p < 0.05), no significant changes in plasma VEGF concentrations were found at day 13 when compared to baseline (p > 0.05). The alteration of plasma VEGF concentrations did not differ between antianhedonic responders and non-responders at days 13 and 26 (all ps > 0.05). Additionally, no significant correlations were observed between the antianhedonic response to ketamine and plasma VEGF concentrations (all ps > 0.05).Conclusion: This preliminary study suggests that the antianhedonic effects of ketamine are not mediated by VEGF.Wei ZhengLi-Mei GuYan-Ling ZhouCheng-Yu WangXiao-Feng LanBin ZhangHai-Shan ShiDan-Feng WangYu-Ping NingYu-Ping NingFrontiers Media S.A.articleketamineVEGFantianhedonic effectmajor depressive disorderresponsePsychiatryRC435-571ENFrontiers in Psychiatry, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
ketamine VEGF antianhedonic effect major depressive disorder response Psychiatry RC435-571 |
| spellingShingle |
ketamine VEGF antianhedonic effect major depressive disorder response Psychiatry RC435-571 Wei Zheng Li-Mei Gu Yan-Ling Zhou Cheng-Yu Wang Xiao-Feng Lan Bin Zhang Hai-Shan Shi Dan-Feng Wang Yu-Ping Ning Yu-Ping Ning Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| description |
Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia item at baseline, day 13 and 26. Plasma VEGF concentrations were examined at the same time points as the MADRS.Results: Despite a significant reduction in anhedonia symptoms in individuals with treatment-refractory MDD (n = 59) or BD (n = 19) after they received repeated-dose ketamine infusions (p < 0.05), no significant changes in plasma VEGF concentrations were found at day 13 when compared to baseline (p > 0.05). The alteration of plasma VEGF concentrations did not differ between antianhedonic responders and non-responders at days 13 and 26 (all ps > 0.05). Additionally, no significant correlations were observed between the antianhedonic response to ketamine and plasma VEGF concentrations (all ps > 0.05).Conclusion: This preliminary study suggests that the antianhedonic effects of ketamine are not mediated by VEGF. |
| format |
article |
| author |
Wei Zheng Li-Mei Gu Yan-Ling Zhou Cheng-Yu Wang Xiao-Feng Lan Bin Zhang Hai-Shan Shi Dan-Feng Wang Yu-Ping Ning Yu-Ping Ning |
| author_facet |
Wei Zheng Li-Mei Gu Yan-Ling Zhou Cheng-Yu Wang Xiao-Feng Lan Bin Zhang Hai-Shan Shi Dan-Feng Wang Yu-Ping Ning Yu-Ping Ning |
| author_sort |
Wei Zheng |
| title |
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| title_short |
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| title_full |
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| title_fullStr |
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| title_full_unstemmed |
Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression |
| title_sort |
association of vegf with antianhedonic effects of repeated-dose intravenous ketamine in treatment-refractory depression |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/74a55e187b2b41f495aeae82377f4f6f |
| work_keys_str_mv |
AT weizheng associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT limeigu associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT yanlingzhou associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT chengyuwang associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT xiaofenglan associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT binzhang associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT haishanshi associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT danfengwang associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT yupingning associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression AT yupingning associationofvegfwithantianhedoniceffectsofrepeateddoseintravenousketamineintreatmentrefractorydepression |
| _version_ |
1718373938032017408 |